Massive european study probes pancreatic cancer link to common diabetes drug

NCT ID NCT05663515

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 24 times

Summary

This study is tracking 24,000 people with type 2 diabetes across seven European countries to see if those who started taking the drug exenatide have a higher risk of developing pancreatic cancer compared to those taking other diabetes medications. Researchers will analyze medical records from 2006 to 2023. The goal is to better understand the long-term safety of exenatide.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Copenhagen, Denmark
Research Site
RECRUITING

Helsinki, Finland
Research Site
RECRUITING

Paris, France
Research Site
RECRUITING

Bergen, Norway
Research Site
RECRUITING

Barcelona, Spain
Research Site
RECRUITING

Vänersborg, Sweden
Research Site
RECRUITING

Edinburgh, United Kingdom
Research Site
RECRUITING

London, United Kingdom

Conditions

Explore the condition pages connected to this study.

PANCREATIC CANCER